The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report

被引：7
|
作者：
Zang, Jing [1 ,2 ]
Horinouchi, Hidehito [3 ]
Hanaoka, Jun [4 ]
Funai, Kazuhito [5 ]
Sakakura, Noriaki [6 ]
Liao, Hu [7 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Ultrasound, West China Womens & Childrens Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Peoples R China
[3] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan
[4] Shiga Univ Med Sci, Dept Surg, Div Gen Thorac Surg, Otsu, Shiga, Japan
[5] Hamamatsu Univ Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[6] Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi, Japan
[7] Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2021年 / 13卷 / 07期
关键词：
RECEPTOR EGFR MUTATION; OPEN-LABEL; 1ST-LINE ERLOTINIB; CHEMOTHERAPY; MULTICENTER; AFATINIB;
D O I：
10.21037/jtd-21-171
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4554 / 4559
页数：6
相关论文
共 50 条
  • [41] Salvage Surgery for Stage IV Non-Small Cell Lung Cancer
    Kojima, Hideaki
    Hayashi, Shoko
    Mizuno, Kiyomichi
    Yasuura, Yoshiyuki
    Shimizu, Reiko
    Kayata, Hiroyuki
    Takahashi, Shoji
    Isaka, Mitsuhiro
    Takahashi, Toshiaki
    Ohde, Yasuhisa
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S777 - S777
  • [42] Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report
    Yang, Zhengyuan
    Lin, Yingcheng
    Wang, Hongbiao
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (08)
  • [43] Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
    Xue, Xinying
    Xue, Qingliang
    Liu, Yuxia
    Pan, Lei
    Wang, Kaifei
    Zhang, Lina
    Wang, Na
    Yang, Bing
    Wang, Jianxin
    ONCOLOGY LETTERS, 2013, 5 (05) : 1599 - 1600
  • [44] Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
    Cho, Kyoung Min
    Keam, Bhumsuk
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Dong-Wan
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (06): : 891 - 898
  • [45] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Matthew K. Wong
    Alvis I. Lo
    Bing Lam
    W. K. Lam
    Mary S. Ip
    James C. Ho
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1023 - 1028
  • [46] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Wong, Matthew K.
    Lo, Alvis I.
    Lam, Bing
    Lam, W. K.
    Ip, Mary S.
    Ho, James C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1023 - 1028
  • [47] Erlotinib as salvage treatment after failure to first-line gefitinib in Non-Small Cell Lung Cancer
    Wong, King Yan Matthew
    Lo, Alvis
    Lam, Jamie
    Lam, Bing
    Ip, Mary S.
    Ho, James C.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S719 - S719
  • [48] Synthesis of Flavokawain B and its Anti-proliferative Activity Against Gefitinib-resistant Non-small Cell Lung Cancer (NSCLC)
    Seo, Young Ho
    Oh, Yong Jin
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (12): : 3782 - 3786
  • [49] Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway
    Xie, Ya-Jia
    Gao, Wei-Na
    Wu, Qi-Biao
    Yao, Xiao-Jun
    Jiang, Ze-Bo
    Wang, Yu-Wei
    Wang, Wen-Jun
    Li, Wei
    Hussain, Shahid
    Liu, Liang
    Leung, Elaine Lai-Han
    Fan, Xing-Xing
    PHARMACOLOGICAL RESEARCH, 2020, 159
  • [50] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
12345